SCHEDULE 13G/A 0001515937 XXXXXXXX LIVE 1 Common Shares, with no par value 09/30/2025 0001581178 Eupraxia Pharmaceuticals Inc. 29842P105 201-2067 Cadboro Bay Road Victoria A1 V8R 5GR Rule 13d-1(d) Robert Disbrow Z4 0 3568150 0 3568150 3568150 N 7 IN (1) Rows 7, 9 and 11 includes (a) 3,068,150 shares of the Issuer's (as defined below) common shares, with no par value (the "Common Shares") and 200,000 Common Shares underlying Issuer's Series 1 preferred shares, with no par value (the "Preferred Shares") jointly owned by Robert Disbrow and Kim Kawaguchi, husband and wife (the "Disbrows"); and (b) 300,000 Common Shares held by the children of the Disbrows. The Disbrows disclaim beneficial ownership of the Common Shares held by their children. (2) Row 13 is calculated based on the Common Shares and Preferred Shares, beneficially owned by the Reporting Person relative to the Issuer's 50,598,331 outstanding Common Shares, as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 4, 2025, plus the 200,000 Preferred Shares. Eupraxia Pharmaceuticals Inc. 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada, V8R 5GR This Schedule 13G is being filed by Robert Disbrow (the "Reporting Person"). 200 Burrard Street, Suite 700, Vancouver, BC V6C 3L6 Canada 3,568,150 7.0 0 3,568,150 0 3,568,150 Y Y Y Y Y Y Robert Disbrow /s/ Robert Disbrow 11/14/2025